Date: Thu, 03 Dec 98 00:28:00 EST From: yoyi31@msn.com To: londhs13@worldnet.att.net Subject: SNN Update Message-ID: <359DFE77.4AC9@erols.com>
index | next in thread | raw e-mail
SNN is ONLY sent to subscribers who have asked to be on our
list. If you wish to unsubscribe please forward a blank e-mail to:
j490@usa.net
**************************************************
December 2 1998
SNN - UPDATE
NUONCOLOGY LABS INC
NLAB - OTC BB
NuOncology Labs Inc. continues to move up strongly. The
stock closed today at $9.72 up 53c on the day to reach
another new high.
SNN originally profiled NuOncology Labs Inc at $5.46 on
July 9 of this year and again at $4.00 on October 25th.
This stock is attracting serious investor attention and looks
as though it will easily break through the $10 mark by
weeks end. SNN expects the market is anticipating either
a news release on NLAB's cancer treatment (Arglabin) or
possibly the corporate finance side of NuOncology's
business.
PLEASE NOTE: SNN will be releasing a NEW PROFILE
on a company in the WASTE TECHNOLOGY industry
in the next 48 hours - watch for your copy.
We have reproduced a copy of a letter that was sent out
to subscribers of StreetSignals and the Waaco Kid
yesterday (Monday December 1st).
******************************************************************
TODAY'S FEATURE: NuOncology Labs (NLAB)
******************************************************************
NuOncology Labs has been featured several times on
StreetSignals and in the proceedings of the Waaco Kid
since it opened for trading below 6 last quarter. It closed
Monday at an all-time high. Momentum indicators have
been highly positive during its recent rally, while the stock
nearly doubled.
Observers of the company suggest that the rally may
not be over, and would not be surprised to see a further
substantial move over the next few weeks.
******************************************************************
The company's official press releases map out numerous
positive trends as NLAB builds out its business plans:
In August, NLAB completed the acquisition of all the
outstanding and issued shares of NuOncology Labs, Inc.
(NuLab), a private Virginia Corporation. The company
noted that it now would participate in the multi-billion
dollar cancer treatment industry by supporting the
research and marketing of a promising cancer treatment
along with the delivery of predictive tests for the
optimization of contemporary cancer treatment. "Both
activities could greatly improve clinical outcomes while
reducing treatment costs," said NLAB, "NuLab
management will now focus on revenue and market
share growth for our oncology laboratory operations and
services which provide a full menu of predictive tests on
tissue biopsies, including chemosensitivity assays
(CSA's), while our scientific team continues development
of our lead cancer treatment compound, Arglabin."
A few days later, the Company announced additions to its
Board of Directors and Management team, culled from
experts in oncology research, business development,
international commerce, and product marketing.
Two weeks later, NLAB began testing and validating the
scientific information generated from the Institute of
Phytochemistry and the Cancer Curing Hospital,
Karaganda, Kazakhstan, on the drug Arglabin. From the
official press release:
Arglabin, NuOncology Labs' lead cancer treatment
compound, was developed in Kazakhstan. Patents have
been filed for this plant-derived compound, and it is already
approved for cancer treatment in special clinics in
Kazakhstan and other republics of the former Soviet Union.
Over 200 patients with a variety of cancers have been
treated with Arglabin with very promising results and few
side effects.
Published data shows that Arglabin inhibits or stops the
growth of several types of tumors, both alone and in
combination with other compounds, more effectively than
most current chemotherapy drugs ("Arglabin. Its
Structure, Properties, and Usage," Institute of
Phytochemistry, Republic of Kazakhstan, 1997).
It has none of the severe side effects usually associated
with chemotherapy, does not suppress the patient's
immune system, and appears to have a very low level of
toxicity.
Plans have been initiated to develop registration for
Arglabin as an ethical pharmaceutical in the United States
and other countries outside the former Soviet Union. As
well, plans are being developed for clinical trials aimed at
securing FDA approval for use of Arglabin for cancer
treatment in the U.S. The company then intends to
license the technology to a major pharmaceutical
company for formal FDA testing, manufacturing, sales
and distribution.
By September, NLAB found it necessary to move to new
facilities, 5 times larger than the former labs. It is
estimated that this facility is capable of performing testing
to the rate of some 1000 comprehensive predictive profiles
per month, as well as providing areas for drug development
and general R&D.
Perhaps most significant in this path of development is the
most recent announcement by NuLab that it has engaged
EBI Securities Corp. to provide consulting services and
advice to NuOncology Labs concerning business and
financial planning, corporate organization and structure,
private and public equity and debt financing, acquisitions,
mergers and other similar business combinations.
********************************************************************
NLAB, then, has been mapping out clear paths of
progress, and appears to have been quietly gathering
support for its stock in the past few weeks, without any
actual announcements regarding the outcome of the
testing and validation trials involving Arglabin. The recent
advance in the price of shares appears, however, to
suggest that the Street suspects any forthcoming
announcements regarding Arglabin could be positive.
Trading volume rose significantly during November's rally,
suggesting that the Company has attracted added
Institutional support. PowerSignals has learned that
NLAB will be presenting information to the European
investment community in the next 10 days.
Unlike other biotech's, NLAB will not be solely dependent
on the success of its lead compounds. NLAB intends to
establish a series of predictive oncology testing labs
utilizing its proprietary technologies. The benefit of
predictive testing to patients is clear. NLAB technology
will enable doctors to test patients to determine which
modes of therapy might work best on any given individual
before actually administering a course of treatment, which
can be notoriously rife with unpleasant and painful side
effects, and still prove the incorrect and ineffective
treatment for that person.
Naturally, if Arglabin proves as effective in trials as the
Company hopes, the revenues derived via licensing the
compound to a major pharmaceutical company for formal
FDA testing, manufacturing, sales, and distribution could
become substantial.
Should the Street come to believe that NLAB could turn
profitable in its testing operations, and have further proof
of the effectiveness of Arglabin as a cancer treatment, the
shares of NLAB could be expected to follow the course of
numerous other stocks of companies pursuing quality
cancer treatments higher.
*******************************************************************
The above article is copyright Capital Markets Communica-
tions. All Rights Reserved.
*******************************************************************
As a subscriber to SNN you have agreed to have read and
fully understand the SNN disclaimer located at:
http://206.132.179.167/disclaimer1
To Unsubscribe: send mail to majordomo@FreeBSD.org
with "unsubscribe freebsd-doc" in the body of the message
help
Want to link to this message? Use this
URL: <https://mail-archive.FreeBSD.org/cgi/mid.cgi?359DFE77.4AC9>